Compound ID | 2931
V-triguan (Vancomycin-polyguanidino dendrimer conjugate)
Class: Glycopeptide
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Active against carbapenem-resistant, colistin-resistant, and susceptible Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, vancomycin-resistant Enterococcus faecium, and methicillin-resistant and -susceptible Staphylococcus aureus; disrupts integrity of cell membrane (membrane-active agent; V-triguan) and targets cell wall synthesis (vancomycin) |
| Description: | Semisynthetic compound; vancomycin conjugate with dendrimerically displayed guanidinium groups (V-triguan 6C and V-triguan 2C); no mammalian cell cytotoxicity at 160 uM (highest tested) |
| Institute where first reported: | Department of Chemistry, Stanford University, Stanford, California 94305, United States |
| Year first mentioned: | 2024 |
| Development status: | Experimental |
| External links: | |
| Citation: | https://pubs.acs.org/doi/10.1021/acsinfecdis.3c00168 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.